Krystal's topical gene therapy gains steam, prompting analyst group to boost sales projection

At the start of its first-ever conference call to present its quarterly numbers, Krystal Biotech CEO Krish Krishnan was quick to point out that the company’s positive earnings for the third quarter can be attributed to its recent sale of an FDA priority review voucher (PRV) for $100 million.